Sperm-associated antigen 5 is a potential biomarker for poor prognosis in breast cancer.

biomarker breast cancer sperm-associated antigen 5

Journal

Oncology letters
ISSN: 1792-1074
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Jan 2019
Historique:
received: 18 03 2018
accepted: 15 10 2018
entrez: 19 1 2019
pubmed: 19 1 2019
medline: 19 1 2019
Statut: ppublish

Résumé

Sperm-associated antigen 5 (SPAG5) is currently considered to serve a role in promoting tumor cell growth and is overexpressed in several types of human cancer. However, to the best of our knowledge, the association of SPAG5 with molecular subtypes of patients with breast cancer (BC) remains to be fully investigated. Reverse transcription-quantitative polymerase chain reaction and immunohistochemistry on tissue microarrays were used in the current study to detect the expression levels of SPAG5 mRNA and protein, respectively, in BC. The association between SPAG5 mRNA and protein levels, and clinical characteristics and prognostic information were investigated. SPAG5 mRNA and protein levels were identified to be higher in BC tissues compared with matched adjacent nontumor tissues. High expression level of SPAG5 protein was associated with tumor size, histological grade, estrogen receptor expression, Ki-67 expression, lymph node status, tumor-node-metastasis (TNM) stage and the triple-negative BC subtype. In addition, high expression level of SPAG5 protein was associated with a poor prognosis in patients with BC. In summary, the current study suggests that SPAG5 is a novel and useful prognostic biomarker in BC.

Identifiants

pubmed: 30655876
doi: 10.3892/ol.2018.9729
pii: OL-0-0-9729
pmc: PMC6312992
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1146-1152

Références

Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Mol Reprod Dev. 2001 Aug;59(4):347-9
pubmed: 11468770
Mol Reprod Dev. 2001 Aug;59(4):410-6
pubmed: 11468777
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Mol Cell Biol. 2002 Apr;22(7):1993-7
pubmed: 11884588
Mol Reprod Dev. 2006 Jan;73(1):92-100
pubmed: 16211599
Mol Oncol. 2010 Jun;4(3):209-29
pubmed: 20537966
Breast Cancer Res. 2012 Jan 06;14(1):R5
pubmed: 22225950
Cilia. 2012 Apr 25;1(1):2
pubmed: 23351521
PLoS One. 2014 Jan 09;9(1):e81843
pubmed: 24416132
Exp Cell Res. 2014 Apr 1;322(2):227-35
pubmed: 24424245
Anticancer Drugs. 2014 Sep;25(8):950-7
pubmed: 24949917
Cell Death Dis. 2015 Jun 11;6:e1784
pubmed: 26068792
Ann Oncol. 2016 Jun;27(6):965-74
pubmed: 26940687
J Exp Clin Cancer Res. 2016 Apr 01;35:60
pubmed: 27037000
Lancet Oncol. 2016 Jul;17(7):1004-1018
pubmed: 27312051
Breast J. 2017 Nov;23(6):764-765
pubmed: 28877403
Chin J Cancer Res. 2017 Oct;29(5):411-418
pubmed: 29142460
Gene. 2018 Feb 5;642:241-248
pubmed: 29146194
Acta Oncol. 2018 Jan;57(1):58-66
pubmed: 29164972
Acta Oncol. 2018 Jan;57(1):74-82
pubmed: 29168430

Auteurs

Xiaoli Zhou (X)

Department of Pathology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213003, P.R. China.

Lizhou Jia (L)

Department of Pathology, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China.

Yangyang Sun (Y)

Department of Pathology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213003, P.R. China.

Lingyun Xu (L)

Department of Pathology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University, Changzhou, Jiangsu 213003, P.R. China.

Xudong Wang (X)

Department of Clinical Bio-bank, Nantong University Affiliated Hospital, Nantong, Jiangsu 226001, P.R. China.

Qi Tang (Q)

Department of Pathology, Nanjing Medical University, Nanjing, Jiangsu 211166, P.R. China.

Classifications MeSH